Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Welcome and Introduction to Vi3C

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Sep

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Welcome and Introduction to Vi3C

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

The Interventional Pharmacoeconomic Toolbox Panel Discussion

FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer

AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions

Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care

Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain

Cervical Cancer Nonscreening Increased Over Nearly 2 Decades